{"id":5590,"date":"2012-07-01T09:20:00","date_gmt":"2012-07-01T09:20:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=5590"},"modified":"2021-07-12T07:42:31","modified_gmt":"2021-07-12T07:42:31","slug":"management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/","title":{"rendered":"Management of hepatitis C virus infection in liver transplantation with adacolumn apheresis."},"content":{"rendered":"
\n

G Novelli<\/a> 1<\/a><\/sup>, M Rossi<\/a>, V Morabito<\/a>, G Ferretti<\/a>, R Pretagostini<\/a>, F Ruberto<\/a>, F Pugliese<\/a>, N Guglielmo<\/a>, P B Berloco<\/a> , Transplant Proc. 2012 Sep;44(7):1946-52.<\/p>\n<\/div>\n\n

\n

Recurrent hepatitis C virus (HCV) is a major cause of liver transplant loss, hepatic failure, and retransplantation need. Posttransplantation antiviral therapy in patients with evidence of recurrent disease is the mainstay of management. Although HCV is a hepatocellular pathogen, there is increasing evidence that the virus can infect and persist in other cells. In particular, granulocytes and monocytes\/macrophages are known to constitute extrahepatic sites for HCV replication and dissemination. The aim of this study was to apply Adacolumn apheresis as a possible therapeutic alternative to conventional drug therapy to manage HCV infections. Seven patients who underwent liver transplantation for HCV-related cirrhosis were eligible for the study. The patients underwent 5 1-hour sessions for 5 consecutive days. The first treatment was performed in the anhepatic phase of liver transplantation with the intent to early reduce infected granulocytes and monocytes\/macrophages. The patients were evaluated over the 5 days after inclusion with 3- and 6-months follow-ups. Early apheresis treatments in the anhepatic phase and over the following 4 days after transplantation produced low viral loads in 4 patients, negative viral loads in 2 patients, and increased viremia in 1 patient. At follow-up, the viremia load was stable in 6 patients without increased transaminase levels. At the end of the treatment cycle, almost all immune cells of the 6 patients maintained CD4+\/CD8+ T-cell ratios. The optimal timing of treatment initiation is unknown, but early preemptive therapy is recommended to decrease the risk for recurrent infection. Although this study investigated the responses among a small number of patients, it documented that the Adacolumn changed cellular immunity, promoting early virologic responses.<\/p>\n<\/div>\n\n

\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/22974879\/<\/a><\/p>\n<\/div>\n\n

\n

<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

G Novelli 1, M Rossi, V Morabito, G Ferretti, R Pretagostini, F Ruberto, F Pugliese, N Guglielmo, P B Berloco , Transplant Proc. 2012 Sep;44(7):1946-52. Recurrent hepatitis C virus (HCV) is a major cause of liver transplant loss, hepatic failure, and retransplantation need. Posttransplantation antiviral therapy in patients with evidence of recurrent disease is the mainstay of management. Although HCV is a hepatocellular pathogen, […]<\/p>\n","protected":false},"template":"","scientific_tags":[314,316],"class_list":["post-5590","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-digestive","scientific_tags-nephrology"],"acf":{"sc_authors":""},"yoast_head":"\nManagement of hepatitis C virus infection in liver transplantation with adacolumn apheresis. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Management of hepatitis C virus infection in liver transplantation with adacolumn apheresis. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"G Novelli 1, M Rossi, V Morabito, G Ferretti, R Pretagostini, F Ruberto, F Pugliese, N Guglielmo, P B Berloco , Transplant Proc. 2012 Sep;44(7):1946-52. Recurrent hepatitis C virus (HCV) is a major cause of liver transplant loss, hepatic failure, and retransplantation need. Posttransplantation antiviral therapy in patients with evidence of recurrent disease is the mainstay of management. Although HCV is a hepatocellular pathogen, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-12T07:42:31+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/\",\"name\":\"Management of hepatitis C virus infection in liver transplantation with adacolumn apheresis. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2012-07-01T09:20:00+00:00\",\"dateModified\":\"2021-07-12T07:42:31+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Management of hepatitis C virus infection in liver transplantation with adacolumn apheresis. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/","og_locale":"es_ES","og_type":"article","og_title":"Management of hepatitis C virus infection in liver transplantation with adacolumn apheresis. - Adacyte","og_description":"G Novelli 1, M Rossi, V Morabito, G Ferretti, R Pretagostini, F Ruberto, F Pugliese, N Guglielmo, P B Berloco , Transplant Proc. 2012 Sep;44(7):1946-52. Recurrent hepatitis C virus (HCV) is a major cause of liver transplant loss, hepatic failure, and retransplantation need. Posttransplantation antiviral therapy in patients with evidence of recurrent disease is the mainstay of management. Although HCV is a hepatocellular pathogen, […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/","og_site_name":"Adacyte","article_modified_time":"2021-07-12T07:42:31+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/","name":"Management of hepatitis C virus infection in liver transplantation with adacolumn apheresis. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2012-07-01T09:20:00+00:00","dateModified":"2021-07-12T07:42:31+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-hepatitis-c-virus-infection-in-liver-transplantation-with-adacolumn-apheresis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/5590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=5590"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=5590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}